Evolution of the Average Target: Merck & Co., Inc.

Evolution of the Target Price: Merck & Co., Inc.

Changes in Analyst Recommendations: Merck & Co., Inc.

0fd876013f.aX4TOSeUt7gf6T6PKHlhF0J_6x2jwRKYpjhofnMjqs8.IQl9XhGmhflV3VT-bE1VfXY3gHqVhD_b8GcYNSN707wwCWRwU87oji2gBg~92f8cb85f617cbbc832fef8890219d30
05-18 Regeneron drops after skin cancer treatment fails late-stage trial RE
05-01 Goldman Sachs Adjusts Merck Price Target to $137 From $133 MT
05-01 Wells Fargo Adjusts Merck Price Target to $145 From $150 MT
05-01 Morgan Stanley Raises Price Target on Merck to $112 From $109, Keeps Equalweight Rating MT
04-21 Arcus Biosciences Has Favorable Setup After Merck Belzutifan Failure, Wedbush Says MT
04-21 Leerink Partners Cuts Merck Price Target to $127 From $129, Maintains Outperform Rating MT
04-09 Biopharma Stocks Largely Exempt From Pharma Tariffs, BofA Says MT
04-08 Wolfe Research Adjusts PT on Merck & Co. to $150 From $142, Maintains Outperform Rating MT
04-06 JPMorgan Adjusts Price Target on Merck & Co. to $135 From $125, Maintains Overweight Rating MT
03-31 Jefferies Adjusts Price Target on Merck & Co. to $138 From $132, Maintains Buy Rating MT
03-19 Citigroup Adjusts Price Target on Merck & Co. to $125 From $120, Maintains Neutral Rating MT
03-19 Jefferies Adjusts Price Target on Merck & Co. to $132 From $130, Maintains Buy Rating MT
03-12 Wells Fargo Adjusts Price Target on Merck & Co. to $150 From $135, Maintains Overweight Rating MT
03-03 Wolfe Adjusts Price Target on Merck to $142 From $135, Maintains Outperform Rating MT
03-02 Leerink Partners Adjusts Price Target on Merck & Co to $129 From $128, Maintains Outperform Rating MT
02-20 HSBC Adjusts Price Target on Merck to $135 From $120, Maintains Buy Rating MT
02-20 Barclays Initiates Coverage on Merck With Overweight Rating MT
02-13 Merck Shares Rise After Deutsche Bank Upgrade MT
02-13 Deutsche Bank Upgrades Merck to Buy From Hold, Adjusts Price Target to $150 From $115 MT
02-13 Deutsche Bank Upgrades Merck to Buy From Hold, Adjusts Price Target to $150 From $115 MT
02-12 Argus Adjusts Price Target on Merck to $130 From $110, Maintains Buy Rating MT
02-11 Daiwa Securities Adjusts PT on Merck & Co. to $120 From $86, Maintains Neutral Rating MT
02-11 Analyst recommendations: Cloudflare, Mattel, Qualcomm, Gilead, Hasbro… Zonebourse
02-10 Rothschild & Co Redburn Adjusts Price Target on Merck & Co. to $140 From $135, Maintains Buy Rating MT
02-06 Guggenheim Adjusts Price Target on Merck & Co to $140 From $122, Maintains Buy Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+14.81%
+18.76%
+10.31%
+19.12%
+9.96%
+18.15%
+3.08%
+6.79%
+6.23%
+20.76%
Average +12.80%
Weighted average by Cap. +13.84%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
113.00USD
Average target price
129.74USD
Spread / Average Target
+14.81%
High Price Target
150.00USD
Spread / Highest target
+32.74%
Low Price Target
100.00USD
Spread / Lowest Target
-11.50%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Goldman Sachs
Wells Fargo Securities
Morgan Stanley
Leerink Partners
Wolfe Research
JPMorgan Chase
Jefferies & Co.
Citigroup
HSBC
Barclays
Deutsche Bank Securities
Argus
Daiwa Securities
Rothschild & Co Redburn
Guggenheim
Bernstein
Cantor Fitzgerald
BMO Capital
Scotiabank
Berenberg Bank
TD Cowen
UBS
DBS Bank
Redburn Atlantic
Truist Securities
CFRA
Zacks Investment Research
Societe Generale
BofA Securities
Atlantic Equities
Credit Suisse
SVB Securities LLC
Cowen
SVB Leerink
RBC Capital Markets
RBC Randall Stanicky
JPMORGAN
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
113.00USD
Average target price
129.74USD
Spread / Average Target
+14.81%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. MRK Stock
  4. Consensus Merck & Co., Inc.